Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3515LS1M
Performance in the last:
Follow this Portfolio
1D -1.1 %
1W 0.8 %
2W 4.5 %
1M 5.6 %
3M 3.6 %
6M 8.2 %
9M -3.9 %
1Y -81.3 %
Alpha
-97.2%
Beta
0.75
sharpe-R
-0.93
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.69
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-04 07:50:32
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -86.36%
Max. DrawDown Benchmark -8.41%

This Long-Short strategy aims to find promising assets to invest in for a maximum holding period of 1 Month in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 15.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

For Long-Short model portfolios, the short-selling costs (asset borrowing costs) are not taken into account. This assumption is likely unrealistic, and it is important to understand the short-selling process before employing this type of strategy.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
4

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
AORT Artivion, Inc. Equity Buy 11.48% 1.19%
AXGN AxoGen, Inc. Equity Buy 11.47% -1.81%
INSM Insmed Incorporated Equity Buy 11.85% 12.98%
ACRS Aclaris Therapeutics, Inc. Equity Buy 11.42% -4%
MD Pediatrix Medical Group, Inc. Equity Buy 11.61% -0.57%
MDXG MiMedx Group, Inc. Equity Buy 11.6% -3.17%
ORGO Organogenesis Holdings Inc. Equity Buy 11.44% 2.4%
NUTX Nutex Health Inc. Equity Buy 14.25% 27.3%
RGNX REGENXBIO Inc. Equity Buy 18.2% -3.1%
FATE Fate Therapeutics, Inc. Equity Sell -4.07% 27.43%
ORMP Oramed Pharmaceuticals Inc. Equity Sell -5.07% 9.24%
HAE Haemonetics Corporation Equity Sell -6.6% 10.04%
MDRX Allscripts Healthcare Solutions, Inc. Equity Sell -3.54% 44.44%
HROW Harrow Health, Inc. Equity Sell -6.77% 7.62%
The percentage of cash held in the portfolio is: 12.72%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.48% 1.19%
AXGN AxoGen, Inc. Buy 11.47% -1.81%
INSM Insmed Incorporated Buy 11.85% 12.98%
ACRS Aclaris Therapeutics, Inc. Buy 11.42% -4%
MD Pediatrix Medical Group, Inc. Buy 11.61% -0.57%
MDXG MiMedx Group, Inc. Buy 11.6% -3.17%
ORGO Organogenesis Holdings Inc. Buy 11.44% 2.4%
NUTX Nutex Health Inc. Buy 14.25% 27.3%
RGNX REGENXBIO Inc. Buy 18.2% -3.1%
FATE Fate Therapeutics, Inc. Sell -4.07% 27.43%
ORMP Oramed Pharmaceuticals Inc. Sell -5.07% 9.24%
HAE Haemonetics Corporation Sell -6.6% 10.04%
MDRX Allscripts Healthcare Solutions, Inc. Sell -3.54% 44.44%
HROW Harrow Health, Inc. Sell -6.77% 7.62%
The percentage of cash held in the portfolio is: 12.72%
New Assets Added
None
Assets Removed
Asset Action Perf %
SIGA Sell All -9.55%
Assets Rebalanced
None
2025-02-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.49% 2.41%
AXGN AxoGen, Inc. Buy 11.53% -0.22%
INSM Insmed Incorporated Buy 11.52% 11.1%
ACRS Aclaris Therapeutics, Inc. Buy 11.67% -0.8%
MD Pediatrix Medical Group, Inc. Buy 11.53% -0.14%
MDXG MiMedx Group, Inc. Buy 11.69% -1.36%
ORGO Organogenesis Holdings Inc. Buy 12.21% 10.51%
NUTX Nutex Health Inc. Buy 13.7% 23.71%
SIGA SIGA Technologies, Inc. Buy 10.95% -6.42%
RGNX REGENXBIO Inc. Buy 18.58% 0%
FATE Fate Therapeutics, Inc. Sell -4.12% 25.71%
ORMP Oramed Pharmaceuticals Inc. Sell -5.19% 5.88%
HAE Haemonetics Corporation Sell -6.82% 6.09%
MDRX Allscripts Healthcare Solutions, Inc. Sell -3.83% 39.33%
HROW Harrow Health, Inc. Sell -6.89% 4.86%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • RGNX
Assets Removed
Asset Action Perf %
TGTX Sell All -0.69%
Assets Rebalanced
None
2025-01-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.73% 1.36%
AXGN AxoGen, Inc. Buy 11.7% -1.75%
INSM Insmed Incorporated Buy 12.04% 12.62%
ACRS Aclaris Therapeutics, Inc. Buy 11.88% -2%
MD Pediatrix Medical Group, Inc. Buy 12.48% 4.86%
MDXG MiMedx Group, Inc. Buy 12.06% -1.25%
ORGO Organogenesis Holdings Inc. Buy 12.79% 12.31%
NUTX Nutex Health Inc. Buy 12% 5.09%
SIGA SIGA Technologies, Inc. Buy 11.97% -0.78%
TGTX TG Therapeutics, Inc. Buy 19.35% 0%
FATE Fate Therapeutics, Inc. Sell -4.48% 21.71%
ORMP Oramed Pharmaceuticals Inc. Sell -5.36% 5.88%
HAE Haemonetics Corporation Sell -7.26% 3.05%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.44% 16.33%
HROW Harrow Health, Inc. Sell -7.47% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HROW
  • TGTX
Assets Removed
Asset Action Perf %
ESPR Sell All -14.96%
Assets Rebalanced
None
2025-01-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.6% 1.42%
ESPR Esperion Therapeutics, Inc. Buy 12.37% -10.26%
AXGN AxoGen, Inc. Buy 11.7% -0.6%
INSM Insmed Incorporated Buy 12.04% 13.85%
ACRS Aclaris Therapeutics, Inc. Buy 12.04% 0.4%
MD Pediatrix Medical Group, Inc. Buy 12.04% 2.29%
MDXG MiMedx Group, Inc. Buy 12.04% -0.34%
ORGO Organogenesis Holdings Inc. Buy 12.04% 6.91%
NUTX Nutex Health Inc. Buy 12.47% 10.49%
SIGA SIGA Technologies, Inc. Buy 12.04% 0.94%
FATE Fate Therapeutics, Inc. Sell -4.3% 24%
ORMP Oramed Pharmaceuticals Inc. Sell -5.37% 4.62%
HAE Haemonetics Corporation Sell -7.13% 3.69%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.57% 13.33%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
TGTX Buy All -11.64%
Assets Rebalanced
Asset Action Weight
AXGN Sell -1.98%
ACRS Sell -1.81%
INSM Sell -3.64%
ORGO Sell -23.86%
NUTX Buy 1.71%
SIGA Buy 4.12%
MD Buy 9.28%
MDXG Buy 9.35%
2025-01-23 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.71% 1.82%
ESPR Esperion Therapeutics, Inc. Buy 13.02% -5.98%
AXGN AxoGen, Inc. Buy 14.33% 3.51%
INSM Insmed Incorporated Buy 15.75% 13.81%
ACRS Aclaris Therapeutics, Inc. Buy 14.42% 4%
MD Pediatrix Medical Group, Inc. Buy 2.72% 0.5%
MDXG MiMedx Group, Inc. Buy 2.76% 1.93%
ORGO Organogenesis Holdings Inc. Buy 35.47% 5.11%
NUTX Nutex Health Inc. Buy 9.3% -1.01%
SIGA SIGA Technologies, Inc. Buy 7.88% 0%
TGTX TG Therapeutics, Inc. Sell -5.99% -4.07%
FATE Fate Therapeutics, Inc. Sell -4.35% 23.43%
ORMP Oramed Pharmaceuticals Inc. Sell -5.49% 2.94%
HAE Haemonetics Corporation Sell -7.42% 0.24%
MDRX Allscripts Healthcare Solutions, Inc. Sell -6.12% 5.33%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • SIGA
Assets Removed
Asset Action Perf %
BLUE Sell All -20.97%
Assets Rebalanced
None
2025-01-22 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 8.2% -17.94%
AORT Artivion, Inc. Buy 12.03% 4.5%
ESPR Esperion Therapeutics, Inc. Buy 12.74% -8.12%
AXGN AxoGen, Inc. Buy 14.41% 3.95%
INSM Insmed Incorporated Buy 15.43% 11.34%
ACRS Aclaris Therapeutics, Inc. Buy 14.44% 4%
MD Pediatrix Medical Group, Inc. Buy 2.71% 0%
MDXG MiMedx Group, Inc. Buy 2.81% 3.63%
ORGO Organogenesis Holdings Inc. Buy 35.82% 6.01%
NUTX Nutex Health Inc. Buy 9.41% 0%
TGTX TG Therapeutics, Inc. Sell -6.15% -6.64%
FATE Fate Therapeutics, Inc. Sell -4.29% 24.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.47% 3.36%
HAE Haemonetics Corporation Sell -7.62% -2.33%
MDRX Allscripts Healthcare Solutions, Inc. Sell -6.47% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MDRX
  • NUTX
Assets Removed
Asset Action Perf %
APLS Buy All -9.8%
TNDM Sell All -5.5%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings